{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:04:34Z","timestamp":1790859874352,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Democritus University of Thrace Special Account, 81006"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,11,23]]},"DOI":"10.1038\/s41416-023-02459-9","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:02:08Z","timestamp":1697274128000},"page":"1852-1862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer"],"prefix":"10.1038","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-8585","authenticated-orcid":false,"given":"Ioannis M.","family":"Koukourakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmia","family":"Xanthopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theologos I.","family":"Sgouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kouroupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Giatromanolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Kouloulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zygogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2459_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1098\/rspb.1907.0014","volume":"79","author":"EF Bashford","year":"1907","unstructured":"Bashford EF, Murray JA, Cramer W. The natural and induced resistance of mice to the growth of cancer. Proc R Soc Lond B Biol Sci. 1907;79:164\u201387.","journal-title":"Proc R Soc Lond B Biol Sci."},{"key":"2459_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","volume":"1","author":"M Burnet","year":"1957","unstructured":"Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J. 1957;1:779\u201386.","journal-title":"Br Med J"},{"key":"2459_CR3","unstructured":"Thomas L. Discussion. In: Lawrence HS, editor. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959. p. 529\u201332."},{"key":"2459_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"2459_CR5","unstructured":"Cruz-Tapias P, Castiblanco J, Anaya JM. Major histocompatibility complex: antigen processing and presentation. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: from bench to bedside. Bogota [Colombia]: El Rosario University Press; 2013. Chapter 10."},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41423-021-00634-7","volume":"18","author":"P Anderson","year":"2021","unstructured":"Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol. 2021;18:556\u201365.","journal-title":"Cell Mol Immunol."},{"key":"2459_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharm. 2017;8:561.","journal-title":"Front Pharm"},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.","journal-title":"J Immunother Cancer"},{"key":"2459_CR9","doi-asserted-by":"publisher","unstructured":"Koukourakis IM, Tiniakos D, Kouloulias V, Zyogianni A. The molecular basis of immune-radiotherapy. Int J Rad Biol. 2022. https:\/\/doi.org\/10.1080\/09553002.2023.2144960","DOI":"10.1080\/09553002.2023.2144960"},{"key":"2459_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"2459_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 2021;9:467\u201375.","journal-title":"Lancet Respir Med"},{"key":"2459_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","volume":"78","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, et al. CA184-043, investigators. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78:822\u201330.","journal-title":"Eur Urol."},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/j.clon.2021.12.004","volume":"34","author":"F Slevin","year":"2022","unstructured":"Slevin F, Hanna CR, Appelt A, Cunningham C, Marijnen CAM, Sebag-Montefiore D, et al. The long and the short of it: the role of short-course radiotherapy in the neoadjuvant management of rectal cancer. Clin Oncol (R Coll Radiol). 2022;34:e210\u201317.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2459_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2020.08.038","volume":"493","author":"K Rothkamm","year":"2020","unstructured":"Rothkamm K, Christiansen S, Rieckmann T, Horn M, Frenzel T, Brinker A, et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine\/tipiracil and X-rays. Cancer Lett. 2020;493:179\u201388.","journal-title":"Cancer Lett"},{"key":"2459_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1399-0039.2006.00776.x","volume":"69","author":"T Rodriguez","year":"2007","unstructured":"Rodriguez T, Aptsiauri N, M\u00e9ndez R, Jimenez P, Ruiz-Cabello F, Garrido F. Different mechanisms can lead to the same altered HLA class I phenotype in tumors. Tissue Antigens. 2007;69:259\u201363.","journal-title":"Tissue Antigens"},{"key":"2459_CR16","doi-asserted-by":"publisher","first-page":"104495","DOI":"10.1016\/j.cellimm.2022.104495","volume":"373","author":"IM Koukourakis","year":"2022","unstructured":"Koukourakis IM, Giatromanolaki A, Mitrakas A, Koukourakis MI. Loss of HLA-class-I expression in non-small-cell lung cancer: association with prognosis and anaerobic metabolism. Cell Immunol. 2022;373:104495.","journal-title":"Cell Immunol"},{"key":"2459_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730\u201349.","journal-title":"Cancer Discov"},{"key":"2459_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00262-007-0396-y","volume":"57","author":"FM Speetjens","year":"2008","unstructured":"Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother. 2008;57:601\u20139.","journal-title":"Cancer Immunol Immunother."},{"key":"2459_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamainternmed.2014.511","volume":"174","author":"MS Reimers","year":"2014","unstructured":"Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014;174:732\u20139.","journal-title":"JAMA Intern Med."},{"key":"2459_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ijc.2910370203","volume":"37","author":"F Momburg","year":"1986","unstructured":"Momburg F, Degener T, Bacchus E, Moldenhauer G, H\u00e4mmerling GJ, M\u00f6ller P. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer. 1986;37:179\u201384.","journal-title":"Int J Cancer"},{"key":"2459_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/bjc.1987.218","volume":"56","author":"LG Durrant","year":"1987","unstructured":"Durrant LG, Ballantyne KC, Armitage NC, Robins RA, Marksman R, Hardcastle JD, et al. Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression. Br J Cancer. 1987;56:425\u201332.","journal-title":"Br J Cancer"},{"key":"2459_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1006\/cimm.1996.0200","volume":"171","author":"Z Abdel-Wahab","year":"1996","unstructured":"Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, et al. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol. 1996;171:246\u201354.","journal-title":"Cell Immunol"},{"key":"2459_CR23","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","volume":"64","author":"CT Garnett","year":"2004","unstructured":"Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985\u201394.","journal-title":"Cancer Res"},{"key":"2459_CR24","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/1097-0142(19910501)67:9<2269::AID-CNCR2820670910>3.0.CO;2-Z","volume":"67","author":"M Hareyama","year":"1991","unstructured":"Hareyama M, Imai K, Kubo K, Takahashi H, Koshiba H, Hinoda Y, et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer. 1991;67:2269\u201374.","journal-title":"Cancer"},{"key":"2459_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/2326-6066.CIR-13-0087","volume":"2","author":"AG Chapuis","year":"2014","unstructured":"Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014;2:27\u201336.","journal-title":"Cancer Immunol Res."},{"key":"2459_CR26","doi-asserted-by":"publisher","first-page":"e108122","DOI":"10.1371\/journal.pone.0108122","volume":"9","author":"H Sato","year":"2014","unstructured":"Sato H, Suzuki Y, Ide M, Katoh T, Noda SE, Ando K, et al. HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer. PLoS ONE. 2014;9:e108122.","journal-title":"PLoS ONE"},{"key":"2459_CR27","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488\u201396.","journal-title":"Cancer Res"},{"key":"2459_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.1990.10.1","volume":"10","author":"I Bursuker","year":"1990","unstructured":"Bursuker I, Pearce MT. Production of interferon-gamma by in vivo tumor-sensitized T cells: association with active antitumor immunity. J Interferon Res. 1990;10:1\u201311.","journal-title":"J Interferon Res."},{"key":"2459_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10724-9","volume":"12","author":"D Korentzelos","year":"2022","unstructured":"Korentzelos D, Wells A, Clark AM. Interferon-\u03b3 increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer. Sci Rep. 2022;12:6657.","journal-title":"Sci Rep."},{"key":"2459_CR30","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00262-022-03154-z","volume":"71","author":"M Ito","year":"2002","unstructured":"Ito M, Mimura K, Nakajima S, Saito K, Min AKT, Okayama H, et al. Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases. Cancer Immunol Immunother 2002;71:2293\u2013300.","journal-title":"Cancer Immunol Immunother"},{"key":"2459_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018;9:3868.","journal-title":"Nat Commun."},{"key":"2459_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00262-008-0532-3","volume":"57","author":"N Aptsiauri","year":"2008","unstructured":"Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother. 2008;57:1727\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"2459_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77:839\u201350.","journal-title":"Cancer Res"},{"key":"2459_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"key":"2459_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fphar.2019.00139","volume":"10","author":"Y Li","year":"2019","unstructured":"Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, et al. The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. Front Pharmacol. 2019;10:139.","journal-title":"Front Pharmacol."},{"key":"2459_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2016.06.015","volume":"65","author":"M Hecht","year":"2016","unstructured":"Hecht M, B\u00fcttner-Herold M, Erlenbach-W\u00fcnsch K, Haderlein M, Croner R, Gr\u00fctzmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52\u201360.","journal-title":"Eur J Cancer"},{"key":"2459_CR37","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00432-019-02874-7","volume":"145","author":"TW Chen","year":"2019","unstructured":"Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2019;145:1043\u201353.","journal-title":"J Cancer Res Clin Oncol."},{"key":"2459_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00262-018-2275-0","volume":"68","author":"SF Chiang","year":"2019","unstructured":"Chiang SF, Huang CY, Ke TW, Chen TW, Lan YC, You YS, et al. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother. 2019;68:283\u201396.","journal-title":"Cancer Immunol Immunother."},{"key":"2459_CR39","doi-asserted-by":"publisher","first-page":"e0212978","DOI":"10.1371\/journal.pone.0212978","volume":"14","author":"T Tominaga","year":"2019","unstructured":"Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S, Nagasaki T, et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS ONE. 2019;14:e0212978.","journal-title":"PLoS ONE"},{"key":"2459_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124:687\u201395.","journal-title":"J Clin Investig."},{"key":"2459_CR41","doi-asserted-by":"publisher","first-page":"e1016709","DOI":"10.1080\/2162402X.2015.1016709","volume":"4","author":"SJ Dovedi","year":"2015","unstructured":"Dovedi SJ, Illidge TM. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology. 2015;4:e1016709.","journal-title":"Oncoimmunology"},{"key":"2459_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2022.07.016","volume":"174","author":"QX Wang","year":"2022","unstructured":"Wang QX, Xiao BY, Cheng Y, Wu AW, Zhang T, Wang H, et al. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR\/MSI-H rectal cancer: a multicentre cohort study. Eur J Cancer. 2022;174:176\u201384.","journal-title":"Eur J Cancer"},{"key":"2459_CR43","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. New Engl J Med. 2022;386:2363\u201376.","journal-title":"New Engl J Med."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02459-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02459-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02459-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:04:18Z","timestamp":1700708658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02459-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,23]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02459-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics and Research Committee of the Aretaieion University Hospital approved the study (316\/26\u201303\u20132021), and all patients gave their written informed consent. The study was conducted according to the criteria set by the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients gave written informed consent to use and publish anonymously all clinical and laboratory data for educational and research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}